Technological watch

Nanoparticles in cancer immunotherapies; an innovative strategy

Cancer has been one of the most significant causes of mortality worldwide. Cancer immunotherapy has recently emerged as a competent, cancer?fighting clinical strategy. Nevertheless, due to the difficulty of such treatments, costs, and off?target adverse effects, the implementation of cancer immunotherapy described by the antigen?presenting cell (APC) vaccine and chimeric antigen receptor (CAR) T cell therapy ex vivo in large clinical trials have been limited. Nowadays, the nanoparticles theranostic system as a promising target?based modality provides new opportunities to improve cancer immunotherapy difficulties and reduce their adverse effects. Meanwhile, the appropriate engineering of nanoparticles taking into consideration nanoparticle characteristics such as size, shape, and surface features, as well as the use of these physicochemical properties for suitable biological interactions, provides new possibilities for the application of nanoparticles in cancer immunotherapy. In this review article, we focus on the latest state?of?the?art nanoparticle?based antigen/adjuvant delivery vehicle strategies to professional APCs and engineering specific T lymphocyte required for improving the efficiency of tumor?specific immunotherapy.

Publication date: 23/08/2020

Author: Pourya Nasirmoghadas, Akbar Mousakhani, Farahnaz Behzad, Nasrin Beheshtkhoo, Ali Hassanzadeh, Marzieh Nikoo, Mohsen Mehrabi, Mohammad Amin Jadidi Kouhbanani

Reference: doi:10.1002/btpr.3070



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 870292.